Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

84.33USD
19 Jun 2019
Change (% chg)

$0.91 (+1.09%)
Prev Close
$83.42
Open
$83.14
Day's High
$84.50
Day's Low
$83.09
Volume
1,255,075
Avg. Vol
1,526,583
52-wk High
$84.50
52-wk Low
$60.32

Latest Key Developments (Source: Significant Developments)

Abbott Sets Quarterly Dividend Of $0.32 Per Share
Friday, 14 Jun 2019 

June 14 (Reuters) - Abbott Laboratories ::SETS QUARTERLY DIVIDEND OF $0.32 PER SHARE.  Full Article

Abbott Reports First Quarter GAAP Earnings Per Share Of $0.38 From Continuing Operations
Wednesday, 17 Apr 2019 

April 17 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS FIRST-QUARTER 2019 RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.63 FROM CONTINUING OPERATIONS.Q1 GAAP EARNINGS PER SHARE $0.38 FROM CONTINUING OPERATIONS.Q1 EARNINGS PER SHARE ESTIMATE $0.61 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.15 TO $3.25 FROM CONTINUING OPERATIONS.SEES Q2 ADJUSTED EARNINGS PER SHARE $0.79 TO $0.81 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES Q2 2019 GAAP EARNINGS PER SHARE $0.47 TO $0.49 FROM CONTINUING OPERATIONS.SEES FY 2019 GAAP EARNINGS PER SHARE $1.95 TO $2.05 FROM CONTINUING OPERATIONS.QTRLY TOTAL PEDIATRIC SALES $1,029 MILLION VERSUS $994 MILLION REPORTED LAST YEAR.FIRST-QUARTER WORLDWIDE SALES OF $7.5 BILLION INCREASED 2.0 PERCENT ON A REPORTED BASIS AND 7.1 PERCENT ON AN ORGANIC BASIS.PROJECTS STRONG FULL-YEAR OUTLOOK.QTRLY TOTAL NUTRITION SALES $1,792 MILLION VERSUS $1,756 MILLION REPORTED LAST YEAR.QTRLY TOTAL DIAGNOSTICS SALES $1,841 MILLION VERSUS $1,837 MILLION REPORTED LAST YEAR.ABBOTT FORECASTS SPECIFIED ITEMS FOR Q2 2019 OF $0.32 PER SHARE.SAYS "WE'RE RIGHT ON TRACK WITH OUR EXPECTATIONS TO START THE YEAR".ABBOTT FORECASTS NET SPECIFIED ITEMS FOR FULL YEAR 2019 OF $1.20 PER SHARE.BOARD OF DIRECTORS OF ABBOTT DECLARED COMPANY'S QUARTERLY DIVIDEND OF $0.32 PER SHARE.SAYS "WE'RE TARGETING ANOTHER YEAR OF STRONG SALES AND EARNINGS GROWTH".Q1 REVENUE VIEW $7.47 BILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $0.80 -- REFINITIV IBES DATA.  Full Article

Abbott Announces CE Mark For Alinity M Diagnostics System And Assays
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Abbott Laboratories ::ABBOTT ANNOUNCES CE MARK FOR ALINITY™ M DIAGNOSTICS SYSTEM AND ASSAYS, THE LATEST IN MOLECULAR TECHNOLOGY, TO HELP DELIVER CRITICAL TEST RESULTS AND BENEFITS TO PATIENTS.  Full Article

Abbott Sets Quarterly Dividend Of $0.32 Per Share
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Abbott Laboratories ::SETS QUARTERLY DIVIDEND OF $0.32 PER SHARE.  Full Article

Abbott And Novo Nordisk Partner To Provide Integrated Digital Solution To People With Diabetes Using Insulin
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Abbott Laboratories ::ABBOTT AND NOVO NORDISK ENTER PARTNERSHIP TO PROVIDE INTEGRATED DIGITAL SOLUTION TO PEOPLE WITH DIABETES USING INSULIN.ABBOTT - PARTNERSHIP TO INTEGRATE INSULIN DOSE DATA FROM NOVO NORDISK CONNECTED PENS INTO DIGITAL HEALTH TOOLS COMPATIBLE WITH FREESTYLE LIBRE SYSTEM.  Full Article

Abbott Labs says Received CE Mark For Determine HBsAg 2 Test
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Abbott Laboratories ::RECEIVED CE MARK FOR DETERMINE HBSAG 2 TEST FOR USE WITH SERUM, PLASMA OR WHOLE BLOOD.  Full Article

Abbott Sees FY 2019 Earnings Per Share $1.80 To $1.90 From Continuing Operations
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS 2018 RESULTS AND ISSUES STRONG FORECAST FOR 2019.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.15 TO $3.25 FROM CONTINUING OPERATIONS.SEES Q1 ADJUSTED EARNINGS PER SHARE $0.60 TO $0.62 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2019 GAAP EARNINGS PER SHARE $1.80 TO $1.90 FROM CONTINUING OPERATIONS.SEES Q1 2019 GAAP EARNINGS PER SHARE $0.25 TO $0.27 FROM CONTINUING OPERATIONS.Q4 ADJUSTED EARNINGS PER SHARE $0.81 FROM CONTINUING OPERATIONS.Q4 GAAP EARNINGS PER SHARE $0.37 FROM CONTINUING OPERATIONS.Q4 EARNINGS PER SHARE ESTIMATE $0.81 -- REFINITIV IBES DATA.QTRLY TOTAL PEDIATRIC SALES $1,013 MILLION VERSUS $1,000 MILLION REPORTED LAST YEAR.QTRLY SALES OF $7.77 BILLION VERSUS $7.59 BILLION.Q4 REVENUE VIEW $7.82 BILLION -- REFINITIV IBES DATA.FOURTH-QUARTER WORLDWIDE SALES OF $7.8 BILLION INCREASED 2.3 PERCENT ON A REPORTED BASIS AND 6.4 PERCENT ON AN ORGANIC BASIS.ISSUING FULL-YEAR 2019 GUIDANCE FOR ORGANIC SALES GROWTH OF 6.5 TO 7.5 PERCENT.FORECASTS NET SPECIFIED ITEMS FOR FULL YEAR 2019 OF $1.35 PER SHARE.QTRLY TOTAL NUTRITION SALES OF $1,777 MILLION VERSUS $1,784 MILLION REPORTED LAST YEAR.FORECASTS SPECIFIED ITEMS FOR Q1 2019 OF $0.35 PER SHARE.FY2019 EARNINGS PER SHARE VIEW $3.20, REVENUE VIEW $32.15 BILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE VIEW $0.64 -- REFINITIV IBES DATA.QTRLY TOTAL DIAGNOSTICS SALES OF $1,961 MILLION VERSUS $1,906 MILLION REPORTED LAST YEAR.SAYS CO IS "VERY WELL-POSITIONED HEADING INTO 2019".  Full Article

Abbott To Acquire Cephea Valve Technologies, Inc.
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Abbott Laboratories ::ABBOTT TO ACQUIRE CEPHEA VALVE TECHNOLOGIES, INC..ABBOTT TO ACQUIRE CEPHEA VALVE TECHNOLOGIES, INC..ABBOTT LABORATORIES - FINANCIAL TERMS WERE NOT DISCLOSED.ABBOTT LABORATORIES - FINANCIAL TERMS WERE NOT DISCLOSED..ABBOTT LABORATORIES - EXERCISED OPTION TO BUY CEPHEA VALVE TECHNOLOGIES, A PRIVATELY HELD MEDICAL DEVICE CO.  Full Article

Abbott Raises Quarterly Dividend 14 Pct To $0.32/Share
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Abbott Laboratories ::RAISES QUARTERLY DIVIDEND 14%, INCREASING PAYOUTS FOR 47 STRAIGHT YEARS.INCREASES QUARTERLY DIVIDEND BY 14 PERCENT TO $0.32PER SHARE.  Full Article

Abbott Laboratories-Entered Into A Five Year Credit Agreement On Nov 30
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - ENTERED INTO A FIVE YEAR CREDIT AGREEMENT ON NOVEMBER 30.ABBOTT LABORATORIES - REVOLVING CREDIT AGREEMENT PROVIDES ABBOTT WITH THE ABILITY TO BORROW UP TO $5 BILLION ON AN UNSECURED BASIS.ABBOTT LABORATORIES - ANY BORROWINGS UNDER REVOLVING CREDIT AGREEMENT WILL MATURE AND BE PAYABLE ON FIFTH ANNIVERSARY OF EFFECTIVE DATE.ABBOTT LABORATORIES - ABBOTT TERMINATED ALL COMMITMENTS OUTSTANDING UNDER FIVE YEAR CREDIT AGREEMENT, DATED JULY 10, 2014 WITH BANK OF AMERICA.  Full Article

CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

June 8 Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.